Hepatic RIG-I Predicts Survival and Interferon-α Therapeutic Response in Hepatocellular Carcinoma
2013; Cell Press; Volume: 25; Issue: 1 Linguagem: Inglês
10.1016/j.ccr.2013.11.011
ISSN1878-3686
AutoresJin Hou, Ye Zhou, Yuanyuan Zheng, Jia Fan, Weiping Zhou, Irene Oi‐Lin Ng, Hui‐Chuan Sun, Lun‐Xiu Qin, Shuang‐Jian Qiu, Joyce M.F. Lee, Chung‐Mau Lo, Kwan Man, Yuan Yang, Yun Yang, Yingyun Yang, Qian Zhang, Xuhui Zhu, Nan Li, Zhengxin Wang, Guoshan Ding, Shi‐Mei Zhuang, Limin Zheng, Xiaoling Luo, Yuan Xie, Anmin Liang, Zhugang Wang, Ming Zhang, Qiang Xia, Tingbo Liang, Yizhi Yu, Xuetao Cao,
Tópico(s)Cancer, Hypoxia, and Metabolism
ResumoIn hepatocellular carcinoma (HCC), biomarkers for prediction of prognosis and response to immunotherapy such as interferon-α (IFN-α) would be very useful in the clinic. We found that expression of retinoic acid-inducible gene-I (RIG-I), an IFN-stimulated gene, was significantly downregulated in human HCC tissues. Patients with low RIG-I expression had shorter survival and poorer response to IFN-α therapy, suggesting that RIG-I is a useful prognosis and IFN-α response predictor for HCC patients. Mechanistically, RIG-I enhances IFN-α response by amplifying IFN-α effector signaling via strengthening STAT1 activation. Furthermore, we found that RIG-I deficiency promotes HCC carcinogenesis and that hepatic RIG-I expression is lower in men than in women. RIG-I may therefore be a tumor suppressor in HCC and contribute to HCC gender disparity.
Referência(s)